4-[4-(5-Bromo-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl)-phenyl]-butyric acid

ID: ALA189878

Chembl Id: CHEMBL189878

PubChem CID: 5276673

Max Phase: Preclinical

Molecular Formula: C15H15BrN2O4

Molecular Weight: 367.20

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  O=C(O)CCCc1ccc(Cn2cc(Br)c(=O)[nH]c2=O)cc1

Standard InChI:  InChI=1S/C15H15BrN2O4/c16-12-9-18(15(22)17-14(12)21)8-11-6-4-10(5-7-11)2-1-3-13(19)20/h4-7,9H,1-3,8H2,(H,19,20)(H,17,21,22)

Standard InChI Key:  ZFEWLYYEONBBQQ-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA189878

   4-[4-[(5-Bromo-2,4-dioxo-pyrimidin-1-yl)methyl]phenyl]butanoic acid

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 367.20

Molecular Weight (Monoisotopic): 366.0215

AlogP: 1.75

#Rotatable Bonds: 6

Polar Surface Area: 92.16

Molecular Species: ACID

HBA: 4

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 4.60

CX Basic pKa: ┄

CX LogP: 2.45

CX LogD: -0.30

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.81

Np Likeness Score: -0.57

References

1. Douguet D, Munier-Lehmann H, Labesse G, Pochet S..  (2005)  LEA3D: a computer-aided ligand design for structure-based drug design.,  48  (7): [PMID:15801836] [10.1021/jm0492296]

2. Gasse C, Douguet D, Huteau V, Marchal G, Munier-Lehmann H, Pochet S..  (2008)  Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial activity.,  16  (11): [PMID:18467107] [10.1016/j.bmc.2008.04.045]

3.  (2008)  Aryl, Pyrimidyl Compounds, Pharmaceutical Compositions Comprising them, Their Use as Antimicrobial Agents, 

Source

Source(2):

• Scientific Literature
• Patent Bioactivity Data